Baseline characteristics
| . | MRD . | URD . |
|---|---|---|
| Sample size | 53 | 30 |
| Median age, y (range) | 42 (18-59) | 44 (22-54) |
| Sex, no. (%) | ||
| Male | 27 (51) | 13 (43) |
| Female | 26 (49) | 17 (57) |
| Sex mismatch, donor/recipient, no. (%) | ||
| M/M | 11 (21) | 11 (37) |
| F/F | 15 (28) | 7 (23) |
| F/M | 12 (23) | 2 (7) |
| M/F | 15 (28) | 10 (33) |
| Disease | ||
| AML, no. (%) | 15 (28) | 13 (43) |
| CR1, no. | 7 | 6 |
| More than CR1, no. | 8 | 7 |
| CML, no. (%) | 13 (25) | 6 (20) |
| CP, no. | 10 | 5 |
| AP/BC, no. | 3 | 1 |
| NHL/CLL/HD, no. (%) | 14 (26) | 5 (17) |
| MDS, no. (%) | 6 (11) | 4 (13) |
| Myeloproliferative diseases, no. (%) | 3 (6) | 0 |
| ALL, no. (%) | 1 (2) | 2 (7) |
| CR1, no. | 0 | 1 |
| More than CR1, no. | 1 | 1 |
| Plasma-cell dyscrasia, no. (%) | 1 (2) | 0 |
| . | MRD . | URD . |
|---|---|---|
| Sample size | 53 | 30 |
| Median age, y (range) | 42 (18-59) | 44 (22-54) |
| Sex, no. (%) | ||
| Male | 27 (51) | 13 (43) |
| Female | 26 (49) | 17 (57) |
| Sex mismatch, donor/recipient, no. (%) | ||
| M/M | 11 (21) | 11 (37) |
| F/F | 15 (28) | 7 (23) |
| F/M | 12 (23) | 2 (7) |
| M/F | 15 (28) | 10 (33) |
| Disease | ||
| AML, no. (%) | 15 (28) | 13 (43) |
| CR1, no. | 7 | 6 |
| More than CR1, no. | 8 | 7 |
| CML, no. (%) | 13 (25) | 6 (20) |
| CP, no. | 10 | 5 |
| AP/BC, no. | 3 | 1 |
| NHL/CLL/HD, no. (%) | 14 (26) | 5 (17) |
| MDS, no. (%) | 6 (11) | 4 (13) |
| Myeloproliferative diseases, no. (%) | 3 (6) | 0 |
| ALL, no. (%) | 1 (2) | 2 (7) |
| CR1, no. | 0 | 1 |
| More than CR1, no. | 1 | 1 |
| Plasma-cell dyscrasia, no. (%) | 1 (2) | 0 |
M indicates male; F, female; CR1, first complete remission; more than CR1, beyond first complete remission; CP, chronic phase; AP/BC, acute phase/blast crisis; HD, Hodgkin disease; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia.